Search

Search Constraints

You searched for: Author/Creator SenGupta, Devi

Search Results

1. 548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19. (31st December 2020)

2. 557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients. (31st December 2020)

3. 561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19. (31st December 2020)

4. 72. Remdesivir vs Standard Care in Patients with Moderate covid-19. (31st December 2020)

5. 73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir. (31st December 2020)

6. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Issue 10107 (4th November 2017)

7. Multi-stakeholder consensus on a target product profile for an HIV cure. Issue 1 (January 2021)

8. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Issue 1 (January 2019)

9. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Issue 12 (December 2016)

10. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Issue 5 (May 2017)